智通财经APP获悉，和誉-B(02256)现涨超11%，截至发稿，涨10.77%，报7.61港元，成交额3909.85万港元。
消息面上，和誉近期公布年度业绩。财报显示，公司全年实现营业收入约5.04亿元人民币，同比大幅增长2544%；与此同时，公司录得当期归母净利润2830万元，首次实现年度扭亏为盈。据悉，2024年，和誉就其核心产品匹米替尼(Pimicotinib/ABSK021)与知名跨国药企默克达成BD交易，并由此获得7000万美元首付款。
和誉同时公布，董事会已批准购回股份计划，动用不超过2亿港元于市场购回公司股份。据悉，于2024年3月13日，董事会批准以不超过1亿港元的额度购回股份，以提升股东价值。截至2024年12月31日止年度，公司共购回并注销2259.4万股股份累计涉及金额6870万港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.